Novavax, COVID and mRNA vaccine
On Friday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.3 which represents a slight increase of $1.15 or 9.47% from the prior close of $12.15. The stock opened at $12.32 and ...
Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.
Novavax’s vaccine is based on protein technology, which takes longer to manufacture than mRNA vaccines like those made by Pfizer and BioNTech and Moderna. Protein-based vaccines work by getting ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in ...
Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.
It’s fall, which means it’s time to get updated on the winter season shots. That includes vaccines for flu, RSV (for babies and the elderly) and, for anyone six months or older, COVID-19.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax occupies five sites in Montgomery County totaling about 370,000 square feet. Its footprint includes its headquarters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback